SELLAS Life Sciences Group, Inc. — Director's Dealing 2011

Apr 15, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-04-13

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-04-13	Common Stock	A	135159	—	Acquired	141159	Direct

Footnotes

F1: Received in exchange for 993,739 shares of Apthera, Inc. common stock in connection with merger of Apthera, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.